Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Andreas P. Katsenos, Athena S. Davri, Yannis V. Simos, Ilias P. Nikas, Chryssa Bekiari, Stavroula A. Paschou, Dimitrios Peschos, Spyridon Konitsiotis, Patra Vezyraki & Konstantinos I. Tsamis. (2022) New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs. Expert Opinion on Investigational Drugs 31:1, pages 105-123.
Read now
Read now
Carol H. Wysham, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Michael Pfeifer & Patrick Lefebvre. (2018) Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. Current Medical Research and Opinion 34:6, pages 1125-1133.
Read now
Read now
Awadhesh Kumar Singh & Ritu Singh. (2017) Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. Expert Review of Clinical Pharmacology 10:6, pages 633-647.
Read now
Read now
Articles from other publishers (7)
Кушнарёва Н. Н., Зиныч Л. В., Ковальчук А. В., Прибила О. В. & Шишкань-Шишова Е. А.. (2021) ОЦЕНКА ВЛИЯНИЯ ТЕРАПИИ ИНКРЕТИНОМИМЕТИКАМИ И ГЛИФЛОЗИНАМИ НА ФУНКЦИЮ АЛЬФА И БЕТА-КЛЕТОК ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ У ПАЦИЕНТОВ С СД 2 ТИПА. World Science:3(64).
Crossref
Crossref
Stefanos Torkos, Jacqueline M. Burke & Kathy Zaiken. (2020) Evaluation of Patient Factors Associated With Achieving Goal Hemoglobin A1c in Collaborative Drug Therapy Management Ambulatory Care Clinics by Clinical Pharmacists: A Retrospective Chart Review. Journal of Pharmacy Technology 37:1, pages 3-11.
Crossref
Crossref
Shubing Jia, Zhiying Wang, Ruobing Han, Zinv Zhang, Yuping Li, Xiaotong Qin, Mingyi Zhao, Rongwu Xiang & Jingyu Yang. (2020) Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. Acta Diabetologica 58:1, pages 5-18.
Crossref
Crossref
Chen Zhang, Fei Ye, Jianmin Wang, Ping He, Ming Lei, Longbin Huang, Anbang Huang, Pingming Tang, Hongjun Lin, Yuting Liao, Yong Liang, Jia Ni & Pangke Yan. (2020) Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry 63:13, pages 7108-7126.
Crossref
Crossref
Héctor Eloy Tamez-Perez, Enrique Delgadillo-Esteban, David Soni-Duque, Mayra Ivonne Hernández-Coria & Alejandra Lorena Tamez-Peña. (2017) SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study. Journal of Diabetes & Metabolic Disorders 16:1.
Crossref
Crossref
Haaglim Cho, JungIn Um, Ji-Hyung Lee, Woong-Hee Kim, Wan Seok Kang, So Hun Kim, Hyung-Ho Ha, Yong-Chul Kim, Young-Keun Ahn, Da-Woon Jung & Darren R. Williams. (2017) ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes. Scientific Reports 7:1.
Crossref
Crossref
Natalie Morris. (2016) Type 2 Diabetes Mellitus: Beyond the Beta Cell. EMJ Diabetes, pages 36-46.
Crossref
Crossref